The DNA sequencing market is growing at 12% annually, projected to reach $25 billion by 2030. Current solutions fall short in speed, cost, and scalability. Singulorize fills this gap:

Research Labs: $5 billion segment seeking precision tools.
Diagnostics: $10 billion opportunity in cancer and genetic disease testing.
Personalized Medicine: Untapped potential as costs drop.
With Janus Q1, we’re poised to capture a significant share by making sequencing faster, cheaper, and more accessible.